Ligand Pharmaceuticals to Acquire XOMA Royalty in $740 Million All-Cash Deal
Ligand Pharmaceuticals (LGND) has reportedly agreed to acquire XOMA Royalty (XOMA) for $740 million in an all-cash deal, according to the Wall Street Journal. The transaction values XOMA at $39 per share. The deal is expected to be finalized soon.
Topics: acquisition deal financial news pharmaceuticals